Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis.

Fiche publication

Date publication

juillet 2021

Journal

Transplantation and cellular therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana , Dr DAGUINDAU Etienne

Tous les auteurs :
Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Gouill SL, Béné MC, Chevallier P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34245928

Résumé

The negative impact of high serum ferritin levels (SFL) before and after allogeneic hematopoietic cell transplantation (Allo-SCT) on outcomes is well recognized. However, it is ill-documented in adults receiving haploidentical SCT (Haplo-SCT) with post-transplant cyclophosphamide (PTCY) for hematological malignancies.